Publicacións en colaboración con investigadores/as de Instituto de Investigación del Hospital de La Princesa (4)

2024

  1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

    International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511

  2. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

    Experimental Dermatology, Vol. 33, Núm. 8

  3. Ustekinumab is effective and safe in the long-term treatment of erythrodermic psoriasis: Multicenter study in daily practice

    JEADV Clinical Practice, Vol. 3, Núm. 2, pp. 604-610

2023

  1. Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice

    Journal of the European Academy of Dermatology and Venereology